到 2028 年北美中型制药市场预测 – COVID-19 影响和区域分析 – 按类型（处方药和非处方药）、药物开发类型（内部和外包）、配方（片剂和胶囊、注射剂、喷雾剂和其他制剂）和治疗类别（心血管疾病、疼痛管理、糖尿病、癌症和其他疾病）
No. of Pages: 135 | Report Code: BMIRE00026288 | Category: Life Sciences
No. of Pages: 135 | Report Code: BMIRE00026288 | Category: Life Sciences
北美中型制药市场预计将从2022年的313,406.34百万美元增长到2028年的461,269.34百万美元；预计 2022 年至 2028 年复合年增长率为 6.7%。
慢性疾病患病率上升推动北美中型制药市场的增长。 人口老龄化和生活方式的改变导致常见且代价高昂的长期健康问题的发病率稳步上升。 随着城市化进程的加快，人们采取久坐的生活方式，从而加剧了肥胖和糖尿病 根据世界卫生组织的预测，到 2026 年，慢性病患病率预计将比目前增加 57%。 北美每年都有许多人患上糖尿病，导致改变生活的并发症。根据国际糖尿病联盟 (IDF) 的数据，该地区 2019 年报告了约 4600 万糖尿病病例，预计到 2045 年将增加到 6200 万。 由于慢性病病例不断增加，对医疗保健系统的需求不断增加成为一个主要问题，从而推动北美地区中型制药市场的发展。
通过引入新功能和技术，北美中型制药市场的供应商可以吸引新客户并扩大其在新兴市场的足迹。这一因素可能会在预测期内推动市场以良好的复合年增长率增长。
北美中部规模制药市场细分
北美中型制药市场按类型、药物开发类型、剂型、治疗类别和国家/地区的基础。
基于类型，北美中型制药公司市场分为处方药和非处方药。 2022年，场外交易领域占据更大的市场份额。根据药物开发类型，市场分为内部和外包。 2022年，外包细分市场占据了更大的市场份额。根据剂型，北美中型药品市场分为片剂和胶囊、注射剂、喷雾剂和其他剂型。平板电脑和胶囊细分市场在 2022 年占据最大的市场份额。根据治疗类别，市场分为心血管疾病、疼痛管理、糖尿病、癌症和其他疾病。 2022 年，糖尿病细分市场占据最大的市场份额。按国家/地区划分，北美中型制药市场分为美国、加拿大和墨西哥。 2022 年，美国占据最大市场份额。
Alexion Pharmaceuticals, Inc.；博士健康公司；第一三共有限公司；卫材有限公司；远藤制药公司；马林克罗特；再生元制药公司；和 Sun Pharmaceutical Industries Ltd 是该地区中型制药市场的领先公司之一。
Strategic insights for North America Mid-Size Pharmaceutical involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 313,406.34 Million |
| Market Size by 2028 | US$ 461,269.34 Million |
| Global CAGR (2022 - 2028) | 6.7% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By 类型
|
| Regions and Countries Covered | 北美
|
| Market leaders and key company profiles |
The regional scope of North America Mid-Size Pharmaceutical refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The North America Mid-Size Pharmaceutical Market is valued at US$ 313,406.34 Million in 2022, it is projected to reach US$ 461,269.34 Million by 2028.
As per our report North America Mid-Size Pharmaceutical Market, the market size is valued at US$ 313,406.34 Million in 2022, projecting it to reach US$ 461,269.34 Million by 2028. This translates to a CAGR of approximately 6.7% during the forecast period.
The North America Mid-Size Pharmaceutical Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Mid-Size Pharmaceutical Market report:
The North America Mid-Size Pharmaceutical Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Mid-Size Pharmaceutical Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Mid-Size Pharmaceutical Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Mid-Size Pharmaceutical Market
